SCHEMBL5217878

SCHEMBL5217878

COc1ccc(C)cc1-n1cc(-c2cnc3ccccc3n2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
GLA P06280 1/20 0.45
GAA P10253 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
NPC1 O15118 3/20 0.43
DYRK1B Q9Y463 1/20 0.43
FGFR3 P22607 8/20 0.41
KDR P35968 7/20 0.39
RAB9A P51151 1/20 0.39
FGFR1 P11362 3/20 0.39
FGFR2 P21802 3/20 0.39
FGFR4 P22455 3/20 0.39
FLT3 P36888 2/20 0.39
PDGFRB P09619 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5217439 0.86 NPC1 (0.53) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5219172 0.83 NPC1 (0.50) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5215948 0.81 NPC1 (0.45) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5219466 0.78 NPC1 (0.48) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5217660 0.78 NPC1 (0.51) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5218479 0.77 NPC1 (0.50) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5216692 0.75 MKNK1 (0.57) MAPTALDH1A1NPC1FGFR3KDR
SCHEMBL5215183 0.75 NPC1 (0.48) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5219136 0.75 NPC1 (0.50) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL5215401 0.74 NPC1 (0.51) MAPTALDH1A1SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C MAPT 2547/4885ALDH1A1 2988/4885SMN1; SMN2 4541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.